Dyne Therapeutics, Inc. (NASDAQ:DYN) was rated a Buy with a price target of $25.00 by RBC Capital. The company secured a $275 million loan facility with Hercules Capital to advance therapies for myotonic dystrophy type 1 and Duchenne muscular dystrophy. CEO John Cox expressed confidence in the company’s ability to deliver functional improvements to the neuromuscular community. Dyne Therapeutics focuses on developing therapies for muscle diseases like Duchenne muscular dystrophy. While DYN shows investment potential, other AI stocks may offer greater upside. For more stock recommendations, visit Insider Monkey.

Read more at Yahoo Finance: RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT